Market Movers (8-K)
See all →NASDAQ
Xeris Biopharma announced robust third quarter 2026 financial results, with total revenue up 44% year-over-year, driven by strong Recorlev performance, leading to raised full-year and 2030 revenue outlooks.
Better than expected
NASDAQ
Xeris Biopharma Holdings, Inc. announced the appointment of Menassie Taddese to its Board of Directors, effective November 2, 2026, strengthening its governance and strategic oversight.
NASDAQ
Xeris Biopharma Holdings, Inc. has filed patent infringement lawsuits against multiple defendants concerning its KEVEYIS (dichlorphenamide) product.
NASDAQ
Xeris Biopharma Holdings, Inc. provided an update on its investigational once-weekly subcutaneous levothyroxine, XP-8121, detailing its comprehensive development program and commercial opportunity.
NASDAQ
Xeris Biopharma announced robust second quarter 2026 financial results, featuring a 34% year-over-year increase in net product revenue driven by Recorlev, and tightened its full-year revenue guidance.
NASDAQ
Xeris Biopharma Holdings, Inc. has concluded privately negotiated exchange transactions and a note conversion, resulting in the retirement of all outstanding 8.00% Convertible Senior Notes due 2028.
Quarterly Earnings (10-Q)
See all →NASDAQ
Xeris Biopharma Holdings, Inc. announced a 33.1% increase in total revenue for the six months ended June 30, 2026, driven by significant growth in Recorlev, though a substantial loss on debt extinguishment impacted net results.
Worse than expected
Capital raise
NASDAQ
Xeris Biopharma Holdings, Inc. announced its first quarter 2026 financial results, showcasing significant revenue growth driven by Recorlev, while managing operational expenses and focusing on pipeline development.
Capital raise
Better than expected
NASDAQ
Xeris Biopharma Holdings, Inc. reported a significant increase in total revenue and a shift to positive net income for the third quarter of 2025, driven by robust Recorlev sales.
Capital raise
Better than expected
NASDAQ
Xeris Biopharma Holdings, Inc. reported a significant reduction in net loss and strong revenue growth for the second quarter and first half of 2025, driven by increased sales of Recorlev and Gvoke.
Capital raise
Better than expected
NASDAQ
Xeris Biopharma's Q1 2025 shows revenue growth driven by key products, with a continued focus on commercialization and pipeline development.
Better than expected
Capital raise
NASDAQ
Xeris Biopharma's Q3 2024 results show revenue growth driven by Gvoke and Recorlev, alongside continued investment in their pipeline, particularly XP-8121.
Worse than expected
Capital raise
Annual Reports (10-K)
NASDAQ
Xeris Biopharma Holdings, Inc. reported its first net income since inception in 2025, driven by strong growth in Recorlev sales and overall revenue increase.
Delay expected
Better than expected
Capital raise
NASDAQ
Xeris Biopharma's 2024 10-K filing reveals a company focused on commercial growth and strategic partnerships despite ongoing losses and competitive pressures.
Worse than expected
Capital raise
NASDAQ
Xeris Biopharma's 2023 10-K filing details the company's financial performance, strategic initiatives, and risk factors, emphasizing its focus on commercial growth and innovative product development.
Better than expected
Capital raise
Insider Trading (Form 4)
See all →NASDAQ
Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 25,000 shares of common stock on November 5, 2026 for $12.49 per share.
NASDAQ
Steven Pieper, See Remarks of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on November 2, 2026 for $10.23 per share.
NASDAQ
Beth Hecht, See Remarks of Xeris Biopharma Holdings, Inc., sold 25,000 shares of common stock on November 2, 2026 for $10.23 per share.
NASDAQ
Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on November 2, 2026 for $10.23 per share.
NASDAQ
Menassie Taddese, a Director of Xeris Biopharma Holdings, Inc., reported multiple transactions in common stock on November 2, 2026.
NASDAQ
Steven Pieper, See Remarks of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on October 1, 2026 for $9.41 per share.
Proxy Statements (Def-14A)
NASDAQ
Xeris Biopharma Holdings announces its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.
NASDAQ
Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: Xeris Biopharma Holdings Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Xeris Biopharma Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.
Better than expected
NASDAQ
Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Xeris Biopharma Holdings is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the Employee Stock Purchase Plan.
Better than expected
Schedule 13G - Passive Investments
NASDAQ
Vanguard Capital Management has updated its beneficial ownership filing for Xeris Biopharma Holdings Inc., reporting a 4.98% stake as of September 30, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5% of Xeris Biopharma Holdings Inc. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Xeris Biopharma Holdings Inc. following an internal realignment.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Xeris Biopharma Holdings Inc.